Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Condition(s) studied

Investigational drug(s) / intervention(s)

ADI-001: No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy

Study summary

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

Eligibility

Primary outcome measure(s)

• Long-term safety of Adicet Bio allogeneic γδ CAR T cell products — 15 years
  Occurrence of new Adverse Events of Special interests, Serious AEs and malignancies

Trial sites (5)